<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Oct. 16, 2020 (HealthDay News) — Use of aspirin, metformin, and statins is associated with a lower risk for lung cancer mortality, according to a study published online Sept. 17 in the Journal of Thoracic Oncology<\/i>.<\/p>\n
Jihun Kang, M.D., from Kosin University Gospel Hospital in South Korea, and colleagues used data from 732,199 individuals who had undergone a national health check-up in 2002 to 2003. Lung cancer incidence and mortality were identified, and associations with common medications (aspirin, metformin, and statins) were assessed.<\/p>\n
The researchers found that metformin use had a protective association with lung cancer incidence and mortality in a dose-response fashion. These associations were prominent among participants with a cumulative defined daily dose of metformin \u2265547.5 (per two-year period) versus patients without diabetes. Lung cancer mortality was similarly lower in a dose-dependent fashion with the use of aspirin and statins. Combined use of the three medications showed more prominent protective associations for both lung cancer risk and mortality.<\/p>\n
“Further research is necessary to develop clinically applicable anticancer strategies of these cardiovascular drugs for the reduction of lung cancer and related mortality,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n